Home » GENENTECH FILES APPLICATION FOR LYMPHOMA DRUG
GENENTECH FILES APPLICATION FOR LYMPHOMA DRUG
Genentech and Biogen Idec have turned in a supplemental use application for Rituxan, their lymphoma drug, to the FDA.
The companies submitted data from a Phase III clinical trial in which Rituxan was used against a different type of lymphoma than it is already approved to treat. Rituxan is already approved for several uses, including as a single agent in patients with relapsed or refractory low-grade or follicular CD20-positive, B-cell non-Hodgkin's lymphoma. The new application asks the FDA to allow its use in previously untreated patients with the disease in combination with other chemotherapy agents like CVP or CHOP.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May